Campath-1H in renal transplantation: The University of Wisconsin experience

Surgery

Volumn 136, Issue 4, 2004, Pages 754-760

  Knechtle, Stuart J ^b   Fernandez, Luis A ^a   Pirsch, John D ^a   Becker, Bryan N ^a   Chin, L Thomas ^a   Becker, Yolanda T ^a   Odorico, Jon S ^a   D'Alessandro, Anthony M ^a   Sollinger, Hans W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 4744354630     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2004.06.015     Document Type: Article

References (13)

1. H. Waldmann, and G. Hale The history of alemtuzumab (Campath-1H) antibody: chronic lymphocytic leukemia CLL-The Cutting Edge 6 2001 2 4
2. G. Hale, M.Q. Xia, H.P. Tighe, M.J. Dyer, and H. Waldmann The campath-1 antigen (Cdw52) Tissue Antigens 35 1990 118 127
3. G. Hale CD52 antigen as a target for immunotherapy Transplant Rev 17 suppl 2003 S8 S9
4. S.J. Knechtle, D. Vargo, J. Fechner, Y. Zhai, J. Wang, and M.J. Hanaway FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts Transplantation 63 1997 1 6
5. R. Calne, P. Friend, S. Moffatt, A. Bradley, G. Hale, and J. Firth Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients Lancet 351 1998 1701 1702
6. R. Calne, S.D. Moffatt, P.J. Friend, N.V. Jamieson, J.A. Bradley, and G. Hale Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients Transplantation 68 1999 1613 1616
7. S.J. Knechtle, J.D. Pirsch, J.H. Fechner Jr., B.N. Becker, A. Friedl, and R.B. Colvin Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study Am J Transplant 3 2003 722 730
8. L.C. Racusen, K. Solez, R.B. Colvin, S.M. Bonsib, M.C. Castro, and T. Cavallo The Banff 97 working classification of renal allograft pathology Kidney Int 55 1999 713 723
9. A.D. Kirk, D.A. Hale, R.B. Mannon, D.E. Kleiner, S.C. Hoffman, and R.L. Kampen Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H) Transplantation 76 2003 120 129
10. D.B. Kaufman Changing role of induction therapy in solid organ transplantation Transplant Rev 17 suppl 2003 S3 S4
11. J.R. Leventhal Alemtuzumab induction and steroid avoidance in kidney and pancreas transplantation Transplant Rev 17 suppl 2003 S16 S17
12. B.J. Nankivell, R.J. Borrows, C.L. Fung, P.J. O'Connell, R.D. Allen, and J.R. Chapman The natural history of chronic allograft nephropathy N Engl J Med 349 2003 2326 2333
13. Z. Wu, S.J. Bensinger, J. Zhang, C. Chen, X. Yuan, and X. Huang Homeostatic proliferation is a barrier to transplantation tolerance Nat Med 10 2004 87 92